Oramed Pharmaceuticals’ quest to expand an insulin tablet for diabetes II has just stalled.
Biotechnology said its phase III trial testing the ORMD-0801 oral insulin capsule failed to control blood sugar compared to placebo. months.
Biotech percentage $ORMP fell more than 70%, from $10. 79 at Wednesday’s close to less than $3 percent Thursday morning.
The phase III trial also failed to meet a secondary endpoint of another blood glucose control, fasting blood glucose, which measured the amount of glucose in the blood of participants who had eaten for at least 8 hours.
As a result, Oramed plans to prevent the progression of its insulin tablet for type II diabetes, he said in a news release. Oramed CEO Nadav Kidron said in a statement: “Today’s result is very disappointing, the positive effects of previous trials. “Full knowledge of the exam is available, we plan applicable learning percentages and long-term plans.
Biotechnology had developed the tablet as an easier way to deliver insulin, rather than a needle or pump. Oramed claims that its capsule can deliver insulin from the competitive pH and enzymes in the gut, and can help it be absorbed through the intestinal wall. Another biotechnology, i2o Therapeutics, in partnership with J
Oramed is also testing its oral insulin remedy for NASH and has an oral GLP-1 analog in early studies, according to its website. Oramed finished a phase II for its oral insulin at NASH in November, but the study was not designed to read about statistically significant differences between the remedy groups.
George Scangos, one of the greatest biotech CEOs of all time, said the time had come to hand over the reins for the last time.
The 74-year-old biotech legend has spent nearly 3 decades in an executive director position. The first in Exelixis, which is still strongly focused on a drug that Scangos has complex in the clinic. The moment “retirement” took hold at Biogen, where he and his team were credited with a big change with the blockbuster MS Tecfidera. And the third comes to Vir, where he traded his Big Biotech credentials for a role as a famous founder on the West Coast, forging a Covid-19 alliance with Hal Barron, then head of the R.
Unlock this article and others by subscribing to one of our paid plans.
Last July, Jeanne Loring stood on a dirt road surrounded by Florida swamps and watched a nearby SpaceX rocket explode in the sky. The payload included one belonging: clusters of cells that mimicked parts of his brain.
For more than two decades, Loring has been at the forefront of a stem cell box that’s poised to become the next step in medicine, but it’s been slow to take off.
Unlock this article and others by subscribing to one of our paid plans.
Gene editing and synthetic intelligence were the topics of social media among industry experts at this year’s JP Morgan Healthcare conference, according to The Harris Poll.
Among the smartest CEOs, JPM Chase’s Jamie Dimon, as well as Flagship’s Noubar Afeyan, Sage Therapeutics’ Barry Greene, Biogen’s Chris Viehbacher and Moderna’s Stéphane Bancel were the most discussed CEOs within Harris’ JPM professional network.
Unlock this story right away and sign up for over 157,200 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Merck is halting a late-stage Keytruda for prostate cancer after interim research showed no improvement in survival, the company said Wednesday. However, the pharmaceutical giant cushioned the blow with a positive look at a separate bile duct cancer.
An independent knowledge monitoring committee that reviewed the Phase III KEYNOTE-991 trial found no improvement in overall survival or radiographic progression-free survival in a mixed Keytruda organization compared to the organization, Merck said in a news release. The trial was conducted on more than 1,200 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or those whose cancer is due to keeping testosterone levels as low as expected after castration.
Pharmaceutical marketers are known for recruiting doctors and celebrities for advertising campaigns. But Novartis has a user for its dry eye drug Xiidra.
Actor Ken Jeong is no longer a practicing doctor, but he remains a prominent Novartis spokesperson for 18 months and is now the brand’s celebrity.
Novartis’ latest TV spot for Xiidra is a parody of a movie trailer with Jeong squinting and rubbing his eyes as he walks through a park, while a loud, ominous voiceover sings, “In a world where dry eye symptoms keep coming back. . . A guy discovers the truth. “
Unlock this story right away and sign up for over 157,200 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Finch Therapeutics’ attempt to make crapsules that save you from a recurrence of a bacterial infection is coming to an end.
For the third time in nine months, Boston-area biotech will lay off staff, this time 95%, up to 77 employees.
As is more familiar in biotechnology these days, Finch turned on red lights early Tuesday and said he would abandon a phase III trial testing his donor’s feces in a capsule for the prevention of recurrent infections with the bacterium Clostridioides difficile, or C. diff.
Unlock this story right away and sign up for over 157,200 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Less than a week after Eisai and Biogen won accelerated FDA approval for their Alzheimer’s drug, lecanemab, editor-in-chief Drew Armstrong spoke personally with Eisai’s U. S. chief executive, Ivan Cheung, who also leads the company’s Alzheimer’s efforts. This transcript has been edited for brevity and clarity.
Drew Amstrong:
Welcome to all. I’m Drew Armstrong, editor-in-chief of Endpoints News, and I’m exceptionally excited to have Eisai’s Ivan Cheung join me. He runs the U. S. company and oversees the Alzheimer’s program. Obviously, everyone had great news last weekwith Lecanemab’s accelerated approval, and congratulations on that. This is a wonderful time for the field, a wonderful time for your company. I need to speak directly because we have 30 minutes and a lot to cover. I am incredibly excited to have this opportunity to communicate with you. Now that I’m in San Francisco, you’re in New Jersey. I’m sorry we can’t be together in person, but I have tons of news from all of you. received this expedited approval.
Unlock this article and others by subscribing to one of our paid plans.
One of the generic brands of a drug used to terminate teen pregnancies sued West Virginia’s attorney general today, alleging that federal law and the FDA supersede West Virginia’s law banning the drug.
The case will most likely be heavily policed, given that medical abortions now account for the majority of all abortions, and that the Supreme Court last September revoked the right to abortion, paving the way for bans in almost all cases. the restrictions are rescinded, as GenBioPro states, “functionally change the FDA’s judgment through the approval of mifepristone and the application of a REMS,” which may only be a check for other states.
What happens when you mix a country music star with a trending fitness challenge and upload a TikTok and Instagram measure?
For Sanofi’s “Knowing RSV” campaign, this meant increased awareness of a common virus that many parents don’t know much about. Fitness problems. However, 72 percent of babies hospitalized with RSV are full-term babies in good physical condition, said Ayanna Santos, director of Sanofi’s RSV franchise in the U. S. U. S.
© Endpoints Company 2023
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.